IDEMIA Announces a Global Partnership With Bosch Building Technologies to Tap the $1bn Biometric Access Control Market
13.7.2021 13:46:00 EEST | Business Wire | Press release
IDEMIA, the leader of Augmented Identity announced today a global partnership with Bosch Building Technologies, a global leader in the security market, to tap the fast-growing biometric access control market. According to market analysts1, this market at $1bn in 2021, will grow to $1.4 by 2024, twice the growth of traditional access control systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005582/en/
(Photo: Business Wire)
This booming market comes from the fact that a growing number of companies understand that for their security, they cannot rely anymore only on simple ID badges, that can be cloned (for older technologies still used by 44% of companies2) or simply stolen. The consequence is that it is never possible to know with certainty who is entering the premises. Biometrics, based on personal, physiological, unforgeable characteristics, provide the highest degree of certainty that the person passing the door is a genuine authorized employee. Bosch Building Technologies offers a software solution that manages different Bosch security subsystems like access control, video surveillance, fire alarm, public address and intrusion systems on one single platform, the Bosch Building Integration System (BIS). This robust and reliable security and life safety system is proven by over 3000 installations integrating 10 million detectors worldwide.
In order to add a biometric layer to BIS, Bosch has selected IDEMIA’s terminals: IDEMIA is the market leader of biometrics for access control with more than 25 year’s experience in that domain, and hundreds of thousands of terminals successfully deployed for a great variety of industries, throughout the world.
Bosch will offer IDEMIA’s flagship contactless biometric terminals:
- MorphoWaveTM , the only terminal in the world capable of scanning and verifying 4 fingerprints in less than 1 second through a quick, simple and fully touchless wave movement of the hand,
- VisionPass the most advanced facial recognition terminal combining 2D, 3D and infrared cameras with IDEMIA’s leading facial algorithms.
Both terminals combine high biometric accuracy, speed and convenience with a fully touchless user experience. They operate efficiently with sanitary masks and are therefore well adapted for Covid-prevention policies. IDEMIA terminals are already integrated with the BIS platform and with most gates and turnstile vendors. This will greatly facilitate deployments in Bosch specific markets with a focus on commercial buildings, industrial and logistics sites, government premises and airports/seaports.
“Bosch stands for quality and reliability. We want to offer innovative and fascinating solutions, as our slogan 'invented for life' states. When our customers are going to deploy biometric terminals for their security, they will be installed for years so we want to offer them the best option”, explains Gregor Schlechtriem, Senior Vice President Bosch Building Technologies Business Unit Access & Intrusion. “Idemia is therefore for us the right partner because of their technology expertise and field-proven quality and performances”, Schlechtriem continues.
“We are delighted to start this global partnership with Bosch”, commented Yves Portalier, EVP Biometric Devices and Automotive at IDEMIA. “The combination of our biometric devices with the BIS platform will be a strong offering for companies looking for a high level of security and user convenience”.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
1 In particular leading market analysis firm OMDIA
2 According to a ASIS International 2019 survey
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005582/en/
Contact information
Press contact
IDEMIA:
Hanna SEBBAH
idemia@havas.com
+33 (0) 6 63 73 30 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom